Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 900

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 900
---
 change in its accounting principles other than in accordance with the applicable
accounting policies;

(vii) extend any loans other than travel or other expense advances to employees in the ordinary course of business
or with the principal amount not exceeding $25,000;

(viii) make or change any material Tax election or change any annual Tax accounting
periods;

(ix) enter into, renew, modify or revise any contract with any current or former Affiliate of Parent;

(x) create any Subsidiary;

(xi) except as set forth on of the Parent Disclosure Schedules, enter into any new Contract with
any broker, finder, investment banker or other Person under which such Person is or will be entitled to any brokerage fee, finders’ fee or other commission in connection with the transactions contemplated by this Agreement;

A-1-41

(xii) except as set forth on of the Parent
Disclosure Schedules, issue, redeem, repurchase or otherwise acquire any capital stock, share capital, membership interests or other securities, or issue any securities exchangeable for or convertible into any share or any shares of its capital
stock, or enter into any agreement with respect to the voting of its capital stock or share capital;

(xiii) withdraw, amend, modify or
supplement the Pre-Signing Certificate of Merger; or

(xiv) undertake any legally binding
obligation to do any of the actions set forth the foregoing clauses (i)-(xiii).

7.3 . From the date hereof through the earlier of (x) termination of this Agreement in accordance with and (y) the Effective Time, other than in connection with the transactions contemplated hereby, neither
the Company, on the one hand, nor the Parent Parties, on the other hand, shall, and such Persons shall cause each of their respective officers, directors, Affiliates, managers, consultants, employees, representatives (including investment bankers,
attorneys and accountants) and agents not to, directly or indirectly, (a) solicit, initiate, engage or participate in, or knowingly encourage or facilitate, negotiations with any Person concerning, or make any offers or proposals related to,
any Alternative Transaction, (b) enter into, engage in or continue any discussions or negotiations with respect to an Alternative Transaction with, or provide any non-public information, data or access to
employees to, any Person that has made, or to the Company’s or Parent’s knowledge, as applicable, is considering making, a proposal with respect to an Alternative Transaction or (